Switch to:
Also traded in: Austria, Germany, Israel, Switzerland, UK

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSE:4523, NSE:SUNPHARMA, SHSE:600518, NYSE:TEVA, TSE:4507, SZSE:000538, SHSE:600196, XPAR:IPN, OCSE:LUN, NYSE:PRGO, TSE:4508, SZSE:000963, XSWX:VIFN, SZSE:300122, JSE:APN, SHSE:600332, HKSE:03320, SHSE:600085, TSE:4581, SHSE:600535 » details
Traded in other countries:MYL.Austria, 6MY.Germany, MYL.Israel, MYL1.Switzerland, 0R5P.UK,
Headquarter Location:UK
Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.

Mylan is one of the world's largest generic pharmaceutical manufacturers with operations in the United States, Europe, Asia, Middle East, Africa, and Australia. Generic drug sales constitute approximately 90% of revenue. Remaining sales come from a handful of branded products, primarily epinephrine injector EpiPen. Mylan also owns Matrix, an Indian active pharmaceutical ingredient manufacturer.

Top Ranked Articles about Mylan NV

Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019
Mylan Announces FDA Approval of Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder)
Mylan to Present at the 37th Annual J.P. Morgan Healthcare Conference
Mylan Adds First Generic for Canasa® Rectal Suppository to Growing Gastroenterology Portfolio
Launch of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering
Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets
Mylan to Present at Nasdaq's 39th London Investor Conference
Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou
Mylan Statement in Response to FDA Warning Letter Relating to Morgantown Plant
Mylan Launches Hulio™ (Biosimilar Adalimumab) in Markets Across Europe
» More Articles for MYL

Ratios

vs
industry
vs
history
PE Ratio 30.88
MYL's PE Ratio is ranked lower than
76% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. MYL: 30.88 )
Ranked among companies with meaningful PE Ratio only.
MYL' s PE Ratio Range Over the Past 10 Years
Min: 15.98  Med: 28.74 Max: 112.56
Current: 30.88
15.98
112.56
Forward PE Ratio 6.21
MYL's Forward PE Ratio is ranked higher than
95% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. MYL: 6.21 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.88
MYL's PE Ratio without NRI is ranked lower than
76% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. MYL: 30.88 )
Ranked among companies with meaningful PE Ratio without NRI only.
MYL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.98  Med: 28.74 Max: 112.56
Current: 30.88
15.98
112.56
Price-to-Owner-Earnings 13.72
MYL's Price-to-Owner-Earnings is ranked higher than
68% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.95 vs. MYL: 13.72 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MYL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.3  Med: 27.76 Max: 310
Current: 13.72
11.3
310
PB Ratio 1.36
MYL's PB Ratio is ranked higher than
74% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. MYL: 1.36 )
Ranked among companies with meaningful PB Ratio only.
MYL' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.14 Max: 7.02
Current: 1.36
0.64
7.02
PS Ratio 1.43
MYL's PS Ratio is ranked higher than
71% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MYL: 1.43 )
Ranked among companies with meaningful PS Ratio only.
MYL' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.69 Max: 3.94
Current: 1.43
0.4
3.94
Price-to-Free-Cash-Flow 16.31
MYL's Price-to-Free-Cash-Flow is ranked higher than
73% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. MYL: 16.31 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MYL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.82  Med: 19.4 Max: 115.12
Current: 16.31
8.82
115.12
Price-to-Operating-Cash-Flow 7.60
MYL's Price-to-Operating-Cash-Flow is ranked higher than
87% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. MYL: 7.60 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MYL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.07  Med: 11.28 Max: 40.9
Current: 7.6
6.07
40.9
EV-to-EBIT 28.16
MYL's EV-to-EBIT is ranked lower than
77% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. MYL: 28.16 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.8  Med: 22.2 Max: 74.2
Current: 28.16
-11.8
74.2
EV-to-EBITDA 9.80
MYL's EV-to-EBITDA is ranked higher than
71% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. MYL: 9.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.6  Med: 11.3 Max: 23.3
Current: 9.8
-22.6
23.3
EV-to-Revenue 2.62
MYL's EV-to-Revenue is ranked higher than
56% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. MYL: 2.62 )
Ranked among companies with meaningful EV-to-Revenue only.
MYL' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.5  Med: 2.7 Max: 5.6
Current: 2.62
1.5
5.6
PEG Ratio 4.86
MYL's PEG Ratio is ranked lower than
84% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. MYL: 4.86 )
Ranked among companies with meaningful PEG Ratio only.
MYL' s PEG Ratio Range Over the Past 10 Years
Min: 0.96  Med: 3.25 Max: 13.61
Current: 4.86
0.96
13.61
Shiller PE Ratio 24.91
MYL's Shiller PE Ratio is ranked higher than
56% of the 252 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.75 vs. MYL: 24.91 )
Ranked among companies with meaningful Shiller PE Ratio only.
MYL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 20.51  Med: 83.19 Max: 169.02
Current: 24.91
20.51
169.02
Current Ratio 1.26
MYL's Current Ratio is ranked lower than
77% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MYL: 1.26 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 4.62 Max: 11.71
Current: 1.26
0.83
11.71
Quick Ratio 0.77
MYL's Quick Ratio is ranked lower than
83% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. MYL: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.36 Max: 8.47
Current: 0.77
0.55
8.47
Days Inventory 128.30
MYL's Days Inventory is ranked lower than
56% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. MYL: 128.30 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 132.36 Max: 150.11
Current: 128.3
88.95
150.11
Days Sales Outstanding 81.57
MYL's Days Sales Outstanding is ranked lower than
56% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. MYL: 81.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 77.49  Med: 91.36 Max: 107.26
Current: 81.57
77.49
107.26
Days Payable 48.10
MYL's Days Payable is ranked lower than
57% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. MYL: 48.10 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 48.1  Med: 66.73 Max: 101.21
Current: 48.1
48.1
101.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.80
MYL's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. MYL: -11.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.8  Med: -1.6 Max: 7.4
Current: -11.8
-25.8
7.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.85
MYL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. MYL: 0.85 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MYL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.56 Max: 5.33
Current: 0.85
0.62
5.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.88
MYL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
92% of the 110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. MYL: 2.88 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
MYL' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.46  Med: 1.78 Max: 7.86
Current: 2.88
0.46
7.86
Price-to-Median-PS-Value 0.85
MYL's Price-to-Median-PS-Value is ranked lower than
52% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. MYL: 0.85 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39  Med: 2.27 Max: 8.45
Current: 0.85
0.39
8.45
Price-to-Peter-Lynch-Fair-Value 3.86
MYL's Price-to-Peter-Lynch-Fair-Value is ranked lower than
94% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.41 vs. MYL: 3.86 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MYL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.67  Med: 1.97 Max: 12.34
Current: 3.86
0.67
12.34
Earnings Yield (Greenblatt) % 3.57
MYL's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. MYL: 3.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.9  Med: 4.3 Max: 12.2
Current: 3.57
-15.9
12.2
Forward Rate of Return (Yacktman) % 14.25
MYL's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 421 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.96 vs. MYL: 14.25 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MYL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.8  Med: 13 Max: 24.9
Current: 14.25
7.8
24.9

More Statistics

Revenue (TTM) (Mil) $11,594.10
EPS (TTM) $ 1.04
Beta1.69
Volatility30.30%
52-Week Range $26.03 - 44.18
Shares Outstanding (Mil)515.63

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 11,463 12,124 12,640 13,166
EBIT (Mil $) 954 1,427
EBITDA (Mil $) 3,296 3,525 4,237 4,384
EPS ($) 1.02 1.57 5.76 6.17
EPS without NRI ($) 1.02 1.57 5.76 6.17
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.36%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK